Current status of intratumour microbiome in cancer and engineered exogenous microbiota as a promising therapeutic strategy

• Published in: Biomedicine & pharmacotherapy Vol. 145; p. 112443
• Main Authors: Chen, Jiawen, Li, Ting, Liang, Jianhao, Huang, Qiqi, Huang, Jian-Dong, Ke, Yiquan, Sun, Haitao
• Format: Journal Article
• Language: English
• Published: France Elsevier Masson SAS 01.01.2022; Elsevier
• Subjects: Animals; Antineoplastic Agents - pharmacology; Bacteria - genetics; Carcinogenesis; Combined Modality Therapy; Disease Progression; Genetic Engineering; Genetically engineered bacteria; Humans; Immunotherapy; Intratumoral bacteria; Microbiota - physiology; Neoplasms - microbiology; Neoplasms - therapy; Therapy; Tumor; Tumor Microenvironment; Therapy; MDSC; NF-kB; PMNs; CTLs; Genetically engineered bacteria; PDA; HPV; siRNAs; DAMPs; BFT; ClyA; CDT; ETBF; IDO; EBV; PAMPs; Tumor; HBV; DSBs; Treg; CagA; TEXs; F. nucleatum; TRAILs; MMP-2; Intratumoral bacteria; CRC; CDDL; ROS; PKS; TLR5; TLR4; PD-1; MMP-9

Research on the relationship between microbiome and cancer has made significant progress in the past few decades. It is now known that the gut microbiome has multiple effects on tumour biology. However, the relationship between intratumoral bacteria and cancers remains unclear. Growing evidence sugg...